(LGND) Ligand Pharmaceuticals - Ratings and Ratios

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) operates at the intersection of innovation and partnerships in the biopharmaceutical sector. Their business model is built on developing and licensing assets, which means they dont bear the full risk of drug development. Instead, they focus on creating value through partnerships, reducing capital requirements and diversifying risk.

Their portfolio is diverse, addressing multiple therapeutic areas. Kyprolis and Evomela target multiple myeloma, while Rylaze treats acute lymphoblastic leukemia. Filspari is in development for rare kidney diseases, and Teriparatide addresses osteoporosis. Ligand also ventures into vaccines with Vaxneuvance and Pneumosil, targeting pneumococcal diseases. Additionally, they offer treatments for postpartum depression (Zulresso) and COVID-19 (Veklury), alongside other formulations like Nexterone and Noxafil-IV.

Ligands Captisol technology is a cornerstone, enhancing drug solubility and stability. This expertise attracts collaborations with major players like Amgen, Merck, and Pfizer, driving their growth through royalties and milestones rather than direct sales.

Financially, Ligands market cap is around $2.17 billion, with a P/E ratio of 46.26 and a forward P/E of 19.12. The P/S ratio of 14.28 reflects high revenue expectations. These metrics indicate a company positioned for growth, leveraging its technology and partnerships to expand its impact in the biopharma industry.